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CASE PRESENTATION
A 42-year-old Indo-Asian woman presented to her local
emergency department with a 1-week history of joint
pains, fatigue, and episodic macroscopic hematuria. She
was prescribed oral cephalexin and analgesia for a
presumed urinary tract infection. Subsequently, she
developed a skin rash, leg edema, and recurrent epistaxis,
prompting withdrawal of her antibiotics. Her condition
failed to improve over the ensuing week, and on return to
the emergency department, she was found to have
developed progressive edema, hematuria, and proteinuria
on urine dipstick testing. Blood tests showed a rise in the
serum creatinine over 1 week from 114 to 240mmol/l. The
patient was transferred to our renal unit for further
investigation and management.
DIAGNOSIS
On direct questioning, she had noted nasal congestion in
addition to epistaxis, but no symptoms of sinusitis or asthma.
She had previously suffered from pulmonary tuberculosis as
a teenager, for which she had been fully treated with appro-
priate antituberculous therapy, and had also undergone a
hysterectomy 3 years previously for menorrhagia.
Her medications included ferrous sulfate for iron
deficiency and hormone replacement therapy. There was no
history of nonsteroidal antiinflammatory use or of herbal
medication intake. She had no history of tobacco or alcohol
use. There was a positive family history of renal disease, with
the patient’s mother having developed end-stage renal failure
of unknown etiology, successfully treated by renal transplan-
tation. The patient was married with three children.
On examination, she was hypertensive with a BP of
151/91mmHg and a pulse rate of 98 beats per minute with
a regular rhythm. There was ankle edema, but the jugular
venous pressure was not raised. There was a non-blanching
purpuric rash over the medial aspect of both lower legs
and ankles. The rest of the examination was unremarkable.
Urinalysis revealed leukocytes 3þ , protein 3þ , and
blood 3þ .
The presenting laboratory investigations are summarized
in Table 1. The chest and sinus radiographs were normal. An
ultrasound scan of the abdomen showed normal sized
kidneys bilaterally, with no evidence of scarring or hydrone-
phrosis, and a normal liver and spleen. Her lung function
tests were within normal limits.
The patient became pyrexial with a temperature of 38 1C.
Her mid-stream urine specimen grew multi-resistant Kleb-
siella species and a lactose-fermenting coliform, for which
treatment with intravenous imipenem was initiated. She
subsequently developed Clostridium difficile-positive diar-
rhea, which was successfully treated with oral metronidazole
and led to the resolution of her fever. As renal function did
not improve and she still had an active urinary sediment, she
proceeded to renal biopsy (Figure 1).
Renal Biopsy showed by light microscopy that almost
all of the glomeruli showed marked hypercellularity, with
both mesangial hypercellularity and mononuclear cells in
the capillary lumens (Figure 1a, b). In addition, occasional
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capillary loops contained eosinophilic thrombi. There was focal
tubular atrophy and mild interstitial edema. The arterioles and
veins appeared normal, but one interlobular artery contained
eosinophilic periodic acid Schiff-positive material in the lumen,
with necrosis in the walls (Figure 1c). Immunoperoxidase
staining showed mesangial and capillary wall IgM and C1q
deposition. On electron microscopy, the capillary loops exam-
ined were patent, whereas the mesangial cells and matrix were
increased. No electron-dense deposits were seen. Overall, the
renal biopsy showed a diffuse endocapillary proliferative
glomerulonephritis with vasculitis. The eosinophilic thrombi
in the glomeruli, with eosinophilic material in an inflamed
artery suggested the possibility of a cryoglobulinemia.
The circulating cryoglobulin titer subsequently returned
with a value of 3200mg/l (NR o20), and was typed as a
type II or mixed cryoglobulin with a monoclonal IgM kappa
component. Repeat serology and quantitative PCR for
hepatitis B and C were entirely negative in the serum and
within the cryoprecipitate. In addition, as her serology
showed an acute parvovirus infection, we tested the
cryoprecipitate and found no increased antiparvovirus
activity in the cryoglobulinemic precipitant compared with
serum, showing that this cryoglobulin was not directed
against this particular virus.
A reduction in the serum creatinine to 124 mmol/l without
further active treatment led to her discharge. However, she
returned 1 week later with symptoms of chest pain, cough,
Table 1 | Laboratory findings on transfer to our institution
Laboratory test At presentation
At final
follow-up
Hemoglobin 9.4 g/dl 12.4 g/dl
White blood count 6.0 109/l 6.8 109/l
Platelets 217 109/l 228 109/l
Sodium 137mmol/l 140mmol/l
Potassium 5.5mmol/l 3.8mmol/l
Urea 17.8mmol/l 4.2mmol/l
Creatinine 164mmol/l 64mmol/l
Corrected calcium 2.57mmol/l 2.60mmol/l
Phosphate 1.65mmol/l 0.8mmol/l
Albumin 28 g/l 41 g/l
Blood glucose 6.1mmol/l 6.8mmol/l
C-reactive protein 31mg/l (NR 0–10) 7mg/l
Antistreptolysin O titers Negative
Urinary protein:creatinine ratio (PCR) 75 g/mg (NR
o20)
No protein
detected
Anti-GBM Negative
Anti-ENA Negative
ANA Negative
Anti-dsDNA Negative
Anti-neutrophil cytoplasm antibody
(ANCA)
Negative
Anti-cardiolipin antibodies Negative
Complement C3 levels 0.86 g/l (0.7–1.7) 1.32 g/l
Complement C4 levels 0.01 g/l
(0.16–0.54)
0.27 g/l
Hepatitis C antibody and mRNA PCR Negative
Hepatitis B surface antigen Negative
Anti-parvovirus IgM and IgG Positive
ANA, anti-nuclear antibody; ENA, extractable nuclear antigen; GBN, glomerular
basement membrane antibody; Ig, immunoglobulin.
Figure 1 |Renal biopsy taken at the time of presentation after treatment of the urinary tract infection. (a) Glomerulus showing
global hypercellularity (hematoxylin and eosin staining (H&E)). (b) Periodic acid-Schiff stain highlights the presence of mononuclear
cells within capillary lumens. (c) Artery showing fibrinoid necrosis (H&E); original magnification  400
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and hemoptysis. Her hemoglobin had dropped to 7.8 g/dl
and serum creatinine was 134 mmol/l. A chest radiograph
showed cardiomegaly and her electrocardiogram showed
low-voltage complexes. An echocardiogram revealed a
nondilated left ventricle with moderate to severe impairment,
global hypokinesis, and a moderate pericardial effusion. Bone
marrow examination revealed no evidence of lymphoproli-
ferative abnormality or other secondary cause of cryoglobu-
linemia (Table 2).
She was transfused with 2U of blood, and was treated
with immunosuppression, consisting of daily oral steroids
starting at 1mg/kg, which subsequently tapered, and two
doses of rituximab (1 g), 14 days apart.
After treatment, she made a significant improvement, with
resolution of her pleural and pericardial effusions, and a fall
in serum creatinine to 79 mmol/l (Figure 2). Her cryoglobulin
levels fell to within normal limits over the course of 4
months, and there was a corresponding normalization of her
complement C4 levels (Figure 2). She is currently in full
remission, 18 months after presentation, off all oral steroids
and maintained only on angiotensin receptor blockade for
mild hypertension. Interestingly, she has maintained this
remission despite reconstitution of her circulating B cells.
DISCUSSION
We describe a patient with type II, mixed essential
cryoglobulinemia (MEC) presenting with cryoglobulinemic
glomerulonephritis, accompanied by myocardial dysfunction,
and pericardial and pleural effusions. The illness developed
coincidentally with an acute parvovirus infection, and was
complicated by concomitant urinary tract and gastrointest-
inal infections. The renal impairment due to cryoglobuli-
nemic glomerulonephritis was treated successfully with oral
steroids and anti-CD20 antibody.
Mixed (type II) cryoglobulinemia is characterized by the
formation of immune complexes (polyclonal IgG and mono-
clonal IgM) that precipitate when the temperature decreases
below 37 1F and redissolve on warming. The monoclonal IgM
autoantibody is a rheumatoid factor, with activity against the Fc
portion of other immunoglobulins. Other causes and features
of cryoglobulinemia are summarized in Table 2. Deposition of
immune complexes leads to small-vessel vasculitis with comple-
ment activation through the classical pathway, reflected by
low serum C4 and CH50 levels, and usually a normal C3 level.
The resulting syndrome most frequently involves the skin, joints,
nerves, and kidney. Renal involvement is common with a
prevalence of up to almost 50%, presenting with non-nephrotic
proteinuria, hematuria, and variable renal impairment.
Identification of the etiology in mixed cryoglobulinemia is
important as it may significantly alter both prognosis and
management (Table 2). An association between hepatitis C
and cryoglobulinemia was first made in 1992 through
quantitative assays of hepatitis C virus (HCV) antibody in
whole serum, cryoprecipitates, and supernatants.1 Although
other cases may be related to other viral infections or
autoimmune disease (Table 2), recent data have consistently
indicated that the majority of cases are associated with HCV
infection, with up to 88% of cases in one study.2
In contrast to the experience in Southern Europe, our
current cohort of 14 patients with biopsy-proven cryoglo-
bulinemic glomerulonephritis, followed in a large urban UK
teaching hospital, has showed that only 7.1% associated with
Table 2 | Classification and etiology of cryoglobulins
Cryoglobulin Features Etiology
Type I Monoclonal Ig (mostly IgM) Waldenstrom’s macroglobulinemia
Multiple myeloma
Chronic lymphocytic leukemia
B-cell proliferative disorders
Type II (mixed) Monoclonal Ig (mostly IgM) with rheumatoid factor activity
Polyclonal IgG
HCV, HBV, EBV, non-Hodgkin’s lymphoma
Chronic lymphocytic leukemia
Sjogren’s syndrome
Waldenstrom’s
Unknown (essential)
Type III Polyclonal Ig (mixture of IgM and IgG) Immune complex disease related to:
Autoimmune diseases (SLE, RA, Sjogren’s)
Infections (HCV, HBV, EBV, HIV, endocarditis, post-infection GN,
parasitic disease)
Malignancies
Unknown (essential)
EBV, Epstein-Barr virus; GN, glomerulonephritis; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; Ig, immunoglobulin; RA, rheumatoid
arthritis; SLE, systemic lupus erythematosus.
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Figure 2 |Biochemical and serological response to therapy.
The improvement in serum creatinine, reduction in cryoglobulin
levels, and increase in circulating C4 are all shown. These changes
have persisted despite subsequent reconstitution of her
circulating B cells.
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hepatitis C, 14.2% with hepatitis B, and the rest classified as
MEC. The majority of patients were Caucasians (64.3%),
with the rest being Indo-Asians (21.4%) and Afro-Caribbeans
(14.3%). A separate historical cohort, previously reported
from our institution, also showed a low level of hepatitis B
virus-related disease (8%) and a high incidence (31%) of
subsequent lymphoma, which is typical of MEC.3 Similar
trends in MEC have been noted in other Northern European
cohorts, in which none of the 22 patients with MEC were
found to be HCV positive.4 The discrepancy with the
published literature, mostly from Southern Europe, may
simply relate to the incidence of hepatitis C in the two
populations. This is particularly important as patients with
MEC vasculitis have a poorer outcome and a fourfold
increased risk of developing B-cell non-Hodgkins lymphoma
compared with HCV-related cryoglobulinemic patients.3,5
In addition to excluding hepatitis C as a cause of cryo-
globulinemia in this case, we also excluded parvovirus as a
cause, as the cryoglobulins revealed no concentration of either
IgM or IgG antiparvovirus activity compared with the serum.
However, we cannot exclude a post-infection induction of cryo-
globulins following acute parvovirus exposure.
Treatment of mixed cryoglobulinemia is aimed at limiting
the pathogenic antibody load by limiting B-cell proliferation and
removing circulating cryoglobulins. Immunosuppression has been
reserved for patients with severe disease manifestations, including
membranoproliferative glomerulonephritis, severe neuropathy,
and life-threatening complications.5 Traditionally, a combination
of corticosteroids and agents such as cyclophosphamide or
azathioprine have been used, as well as plasmapheresis. The
cases in which HCV is implicated, antiviral therapy is used
first, combined with immunosuppression in severe disease.6
Importantly, in a large retrospective study of 105 patients
with cryoglobulinemic vasculitis and renal disease, in which
80% were given corticosteroids and/or cytotoxic agents and
67% underwent plasmapheresis, only 14% had a long-lasting
remission, and the 10-year survival rate was just 49%.7 With a
relatively low rate of remission and a high incidence of severe
complications, the development and refinement of safer, more
effective treatment regimes remains the primary goal.
Rituximab, a chimeric monoclonal antibody that binds
the B-cell CD20 antigen, has been widely used in the
treatment of immune-mediated renal disease.8 CD20 appears
at the late pre-B stage of development and is lost during the
terminal differentiation into plasma cells. Therefore, ritux-
imab may be expected to interfere with monoclonal IgM
production, cryoglobulin synthesis, and renal deposition of
immune complexes. A recent review of rituximab treatment
in cryoglobulinemic vasculitis included 57 patients, in which
the cause was non-hepatitis C-related in just 25% of cases.6
Of 57 patients, 18 (32%) had cryoglobulinemic glomerulo-
nephritis, of whom 70% had a complete clinical response
after rituximab therapy.6 However, in these studies, rituximab
has been predominantly used as a second-line treatment
because of nonresponse or intolerance of other treatments,
and was used as first-line therapy in just 2 of 57 cases, both of
which were associated with HCV infection. In addition,
relapses were reported in 39% of cases, although the majority
responded to further anti-CD20 therapy. No differences were
noted in efficacy whether the disease was HCV related or not.
Successful treatment of de novo type III cryoglobulinemic
graft dysfunction with rituximab in renal transplant patients
(non-HCV related in 2 of 7 cases) and in type I cryoglobuli-
nemia has also been reported.9,10 Overall, the anecdotal reports
suggest that rituximab has a good safety profile and results in
amelioration of constitutional symptoms, an increase in C4,
decrease in proteinuria, and improvement in renal function.6
There have been no reports of primary treatment of MEC
glomerulonephritis with rituximab in the literature to date.
However, a well-designed randomized clinical trial is required
to confirm the long-term efficacy of rituximab in comparison
with current standard of care, before it should be considered
a suitable first-line therapy. A phase II trial of rituximab in
HCV-associated cryoglobulinemia is underway, whereas a
similar study in non-viral MEC is yet to be undertaken.
CONCLUSIONS
We have described a case of MEC, which developed in the context
of an acute parvovirus infection, successfully treated with steroids
and rituximab as primary immunosuppressive therapy. Given
the significant morbidity associated with standard immuno-
suppressant therapies, and the number of small cohort studies
already reported using salvage rituximab therapy, primary treat-
ment of MEC glomerulonephritis with rituximab appears to
offer a safe, effective treatment for this condition. However,
randomized studies are required to fully evaluate the benefits.
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